Trimodulin is currently in clinical development for the treatment of patients with severe COVID-19 and for patients with severe community-acquired pneumonia (sCAP).
Trimodulin (IgM Concentrate) is an innovative immunoglobulin therapeutic derived from human blood plasma. Compared to conventional immunoglobulin G (IgG) preparations (IVIGs), Trimodulin contains relevant amounts of antibodies of classes M (IgM) and A (IgA) in addition to IgG.
Based on preclinical research, Trimodulin is thought to act through a number of mechanisms that interfere with pathological processes involved in respiratory failure, severe sepsis and multi-organ failure, eventually leading to death. Due to the variety of polyvalent antibodies present in Trimodulin, the patients’ impaired immune system is supported in various ways. The antibodies bind to different types of pathogens including viruses and bacteria as well as their toxins, and support their clearance by the immune system. Particularly the IgM component in Trimodulin might attenuate dysregulated immune responses and thus prevent the immune system from attacking the body’s own healthy tissue, e.g. the lungs. In this way, Trimodulin may help avoid complications and progression of disease.